Effect of variability of cyclosporine pharmacokinetics on long-term renal allograft survival.
Markell
M S
MS
Department of Medicine, SUNY Health Science Center at Brooklyn 11203, USA.
Homel
P
P
Sumrani
N
N
Hong
J H
JH
Distant
D A
DA
Miles
A M
AM
Sommer
B G
BG
Friedman
E A
EA
D000206:Actuarial Analysis; D000924:Anticholesteremic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002784:Cholesterol / Q000097:blood; D002851:Chromatography, High Pressure Liquid; D016572:Cyclosporine / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D005500:Follow-Up Studies; D005919:Glomerular Filtration Rate; D006084:Graft Rejection / Q000453:epidemiology; D006085:Graft Survival / Q000187:drug effects / Q000502:physiology*; D006801:Humans; D007166:Immunosuppressive Agents / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology / Q000502:physiology*; D008111:Liver Function Tests; D011183:Postoperative Complications / Q000453:epidemiology; D011341:Probucol / Q000009:adverse effects / Q000627:therapeutic use*; D016016:Proportional Hazards Models; D011507:Proteinuria; D012709:Serum Albumin / Q000032:analysis; D013997:Time Factors
D000924:Anticholesteremic Agents; D007166:Immunosuppressive Agents; D012709:Serum Albumin; D016572:Cyclosporine; D002784:Cholesterol; D011341:Probucol